The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Biotech Focus: Live Lactobacilli as a Solution to Improve Skin Health
Editor's Choice

Biotech Focus: Live Lactobacilli as a Solution to Improve Skin Health

MAY 28, 2019
Crown Laboratories Acquires Xycrobe™ Therapeutics, Inc.
Finance

Crown Laboratories Acquires Xycrobe™ Therapeutics, Inc.

MAY 24, 2019
Synlogic Announces New Clinical Collaboration with Roche
Finance

Synlogic Announces New Clinical Collaboration with Roche

MAY 22, 2019
MaaT Pharma Expands Patent Portfolio with Three Granted Patents
Finance

MaaT Pharma Expands Patent Portfolio with Three Granted Patents

MAY 22, 2019
IMM-ETG: A New European Initiative for Intestinal Microbiome Medicinal Products
Editor's Choice

IMM-ETG: A New European Initiative for Intestinal Microbiome Medicinal Products

MAY 21, 2019
Human gut microbiome physiology can now be studied in vitro using Organ Chip technology
Pharma & Human Health

Human gut microbiome physiology can now be studied in vitro using Organ Chip technology

MAY 20, 2019
Healthy Directions introduces LifeBiome™ – a new line of innovative digestive health supplements
Biotics and Supplements

Healthy Directions introduces LifeBiome™ – a new line of innovative digestive health supplements

MAY 17, 2019
BioCompute and WHISE-Embleema Launch Framework for FDA Drug Submissions
Pharma & Human Health

BioCompute and WHISE-Embleema Launch Framework for FDA Drug Submissions

MAY 15, 2019
Vedanta Biosciences Closes Extended $45.5 Million Series C Financing
Finance

Vedanta Biosciences Closes Extended $45.5 Million Series C Financing

MAY 13, 2019
Synthetic Biologics First Quarter 2019 Operational Highlights and Financial Results
Finance

Synthetic Biologics First Quarter 2019 Operational Highlights and Financial Results

MAY 10, 2019
Modulating the Preterm Gut Microbiota: An Interview with Dr Lindsay Hall
Editor's Choice

Modulating the Preterm Gut Microbiota: An Interview with Dr Lindsay Hall

MAY 9, 2019